Original Article
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
N Engl J Med 2005; 353:2111-2120November 17, 2005
- Abstract
Background
Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but are typically prescribed with minimal or no lifestyle modification. This practice is likely to limit therapeutic benefits.
Methods
In this one-year trial, we randomly assigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care provider in eight visits of 10 to 15 minutes each; lifestyle-modification counseling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling delivered by a primary care provider in eight visits of 10 to 15 minutes each. All subjects were prescribed a diet of 1200 to 1500 kcal per day and the same exercise regimen.
Results
At one year, subjects who received combined therapy lost a mean (±SD) of 12.1±9.8 kg, whereas those receiving sibutramine alone lost 5.0±7.4 kg, those treated by lifestyle modification alone lost 6.7±7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5±8.0 kg (P<0.001). Those in the combined-therapy group who frequently recorded their food intake lost more weight than those who did so infrequently (18.1±9.8 kg vs. 7.7±7.5 kg, P=0.04).
Conclusions
The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.
Media in This Article
Figure 1
Enrollment and Retention.Figure 2
Mean (±SE) Weight Loss in the Four Groups, as Determined by an Intention-to-Treat Analysis (Panel A) and a Last-Observation-Carried-Forward Analysis (Panel B).Article Activity
- Article
Two medications, sibutramine (Meridia, Abbott Laboratories) and orlistat (Xenical, Roche), are currently approved by the Food and Drug Administration for the induction and maintenance of weight loss.1-5 These agents are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy,2,3,6 which is known as lifestyle modification and is delivered in weekly group or individual sessions.7-9 Industry-sponsored trials of weight-loss medications typically have included limited programs of lifestyle modification.5,10,11
This randomized trial compared the efficacy of sibutramine alone (as typically prescribed in primary care practice), group sessions of lifestyle modification alone, and the combination of the two therapies. We expected that the combined treatment would result in significantly greater weight loss than either therapy alone because of the potentially complementary mechanisms of action of the two approaches.11 Sibutramine, a serotonin–norepinephrine reuptake inhibitor, appears to modify internal signals that control hunger (the drive to eat) and satiation (fullness).4,12 In contrast, lifestyle modification teaches patients to control the external environment involving food — for example, by grocery shopping from a list or recording food intake.7-9 Two studies13,14 of fenfluramine (which was withdrawn from the market in 1997 because of its association with valvular heart disease15) suggested that the effects of lifestyle modification and medication would be additive.
Our study included a fourth treatment group that assessed the efficacy of sibutramine combined with brief lifestyle-modification counseling delivered by primary care providers. We anticipated that this intervention would result in significantly greater weight loss than medication alone and could potentially provide a model for delivering lifestyle-modification counseling in primary care practice.16,17
Methods
Subjects
The study involved 180 women and 44 men, 18 to 65 years of age, each of whom had a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 to 45. Eligible subjects were free of uncontrolled hypertension (defined by a blood pressure greater than 140/90 mm Hg); cerebrovascular, cardiovascular, renal, or hepatic disease; and type 1 or 2 diabetes. Women were ineligible if they were pregnant or breast-feeding. The use of medications known to affect body weight, a weight loss of 5 kg or greater in the preceding six months, and the use of selective serotonin-reuptake inhibitors were exclusion criteria. Psychosocial contraindications included bulimia nervosa, substance abuse, clinically significant depression, or current psychiatric care.
Initially, 404 persons responded to advertisements for the study, completed a telephone interview, and appeared to meet eligibility requirements. They met with a psychologist, who described the study's requirements, obtained written informed consent, and assessed their psychosocial status. Also, height, weight, and blood pressure were measured. As shown in Figure 1Figure 1
Enrollment and Retention., a total of 77 applicants elected not to participate and 65 were excluded because of various contraindications. The remaining 262 persons were referred to their family physicians, who obtained a history and performed a physical examination and electrocardiography to determine whether applicants were free of the physical complications described previously; 38 were deemed by their physicians to have contraindications to participation. The family physicians forwarded their findings to the project physician. The 224 persons who passed the medical-screening tests comprised the final sample (Table 1Table 1
Baseline Characteristics of the Subjects.).Treatment Groups
Subjects were randomly assigned to receive one of the four treatments described below. At week 0 (baseline), all subjects were instructed to maintain their usual eating and activity habits. Thereafter, all subjects were prescribed a balanced-deficit diet of 1200 to 1500 kcal per day, with approximately 15 percent of energy derived from proteins, 30 percent or less from fats, and the remainder from carbohydrates. All were encouraged to exercise (walk) 30 minutes a day most days of the week.
Sibutramine Alone
Fifty-five subjects were assigned to receive sibutramine alone. They had eight brief visits (10 to 15 minutes each) with a primary care provider at weeks 1, 3, 6, 10, 18, 26, 40, and 52. During week 1, subjects were given a daily dose of 5 mg of sibutramine (provided by Abbott Laboratories, which otherwise had no involvement in the study), and the dose was increased to 10 mg at week 3 and to 15 mg at week 6. Subjects received a copy of “On Your Way to Fitness,”19 a pamphlet that provides tips for healthy eating and activity. They were not instructed to keep records of food intake or activity, and the primary care providers gave only general encouragement. Weight and vital signs were measured at all visits. The primary care providers included three internists and one nurse practitioner, none of whom specialized in obesity management.
Lifestyle Modification Alone
A total of 55 subjects were assigned to receive lifestyle modification alone. They attended weekly group meetings from weeks 1 through 18, sessions conducted every other week from weeks 20 through 40, and a follow-up visit at week 52. Meetings included 7 to 10 subjects, lasted 90 minutes, and were led by trained psychologists. For the first 18 weeks, sessions followed the LEARN (Lifestyle, Exercise, Attitudes, Relationships, and Nutrition) Program for Weight Control,20 which instructed subjects to complete weekly homework assignments that included keeping daily records of food and calorie intake and physical activity. Records were reviewed at weekly meetings. From weeks 20 through 40, sessions were conducted with the use of the Weight Maintenance Survival Guide.21
Combined Therapy
Sixty subjects were assigned to combined therapy. They were given the same two treatments as those in the first two groups, but with a slight modification. They received sibutramine, attended medical visits, and attended group sessions of lifestyle counseling that followed a version of the LEARN Program for Weight Control22 that was adapted to include sibutramine.
Sibutramine plus Brief Therapy
A total of 54 subjects received sibutramine and met with a primary care provider (10 to 15 minutes per session) on the same schedule as subjects in the group given sibutramine alone. They also were given the two treatment manuals21,22 and were instructed to complete homework assignments, including daily food-intake and activity records, which they reviewed during visits with the primary care providers. (Additional details about treatment implementation are provided in the Supplementary Appendix, available with the full text of this article at www.nejm.org.)
Outcomes
A digital scale (model 6800A, Detecto) was used at all treatment visits to measure subjects' weight while they were dressed in light clothing. Behavioral adherence during the first 18 weeks was assessed in the three groups receiving lifestyle-modification therapy by counting the number of food-intake records completed. For each week, subjects received a score of 0 to 7, reflecting the number of days they completed a record. Completion of food-intake records has been shown to correlate positively with weight loss.16,23,24
Levels of triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, glucose, and insulin were measured at baseline and at weeks 18, 40, and 52 after an overnight fast (Quest Diagnostics). Insulin sensitivity was estimated with the use of the homeostasis model of insulin sensitivity.24 Blood pressure and pulse were measured by research assistants with an automated monitor (Dinamap, model 9300, Johnson & Johnson) on the same schedule as the visits to primary care providers. On each occasion, two readings were taken at one-minute intervals after subjects had been seated for at least five minutes.
Attrition
Thirty-nine subjects (17 percent) did not complete the one-year study. This number includes anyone who attended the first treatment visit but did not return. There were no significant differences in attrition among the four groups (Figure 1). Most of those who dropped out did so because they were dissatisfied with treatment (22 subjects) or had scheduling conflicts (5 subjects). Twelve withdrew because of medical complications. The complications included two pregnancies reported at week 6 of the program; the data on these two women were excluded from the analysis because of the likelihood that they were pregnant at the start of the study.
Statistical Analysis
The sample size was selected to provide the study with a statistical power of 80 percent to detect a 4-kg difference in weight loss at week 52 among those receiving combined therapy as compared with both those receiving sibutramine alone and those receiving lifestyle modification alone. Similar statistical power was available to detect a 4-kg difference between those in the group given drug plus brief therapy and those given sibutramine alone. Preliminary analysis revealed no significant differences among the four groups in baseline characteristics (Table 1). Differences in weight and other outcomes among groups at weeks 18, 40, and 52 were compared with the use of analysis of variance with repeated measures. In cases of a significant treatment effect, Tukey's honestly significant difference test25 was used to identify differences among the four groups.
Data were examined for the 222 subjects who began treatment (excluding the 2 women who were thought to be pregnant before the study began) with the use of the last-observation-carried-forward analysis, a more conservative method than examining only those who completed treatment. An even more conservative intention-to-treat analysis was used for weight change; subjects who discontinued treatment were assumed to have regained 0.3 kg per month after leaving the study.24 Chi-square tests were performed to compare percentages of subjects in each group who lost 5 percent or more of their initial weight. Partial-correlation analysis, which controlled for the effect of treatment group, was used to examine predictors and correlates of weight loss. Data were analyzed with the use of SPSS software (version 11).25
This study was approved by the institutional review board of the University of Pennsylvania and was conducted from January 2000 to August 2003. The authors were solely responsible for designing the study, securing funding, treating subjects, collecting and analyzing the data, and writing the manuscript.
Results
Weight Loss
At one year, subjects who received combined therapy lost a mean (±SD) of 12.1±9.8 kg, whereas those receiving sibutramine alone lost 5.0±7.4 kg, those treated by lifestyle modification alone lost 6.7±7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5±8.0 kg. Subjects in the group receiving combined therapy lost significantly more weight at 1 year, as well as at weeks 18 and 40, than those in the other three groups (P<0.001 by the intention-to-treat analysis) (Figure 2AFigure 2
Mean (±SE) Weight Loss in the Four Groups, as Determined by an Intention-to-Treat Analysis (Panel A) and a Last-Observation-Carried-Forward Analysis (Panel B).). In addition, subjects in the group treated by lifestyle modification alone and those in the group given sibutramine plus brief therapy lost significantly (P=0.05) more weight at week 18 than those in the group given sibutramine alone; there were no other significant differences among these three groups at week 40 or 52. Results of the last-observation-carried-forward analysis yielded the same statistical conclusions (Figure 2B). An analysis of covariance that controlled for the effects of initial weight, age, sex, and race or ethnicity also yielded the same statistical conclusions, with one exception; at week 18, the weight losses in the group treated by lifestyle modification alone and the group given sibutramine plus brief therapy were superior (P=0.05) to those in the group given sibutramine alone in the last-observation-carried-forward analysis but not in the intention-to-treat analysis.At one year, significantly more subjects in the combined-therapy group (73 percent) lost 5 percent or more of their initial weight than did those in the group given sibutramine alone (42 percent), the group treated by lifestyle modification alone (53 percent), and the group given sibutramine plus brief therapy (56 percent) (P=0.05). More subjects in the combined-therapy group (52 percent) also lost 10 percent or more of their initial weight than did those in the three other groups (26 percent, 29 percent, and 26 percent, respectively; P=0.004).
Behavioral Adherence
The mean (±SD) number of food-intake records completed during the first 18 weeks (126 days) of the study was 88.4±32.7 in the group treated by lifestyle modification alone, 91.5±35.9 in the combined-therapy group, and 61.0±40.0 in the group given sibutramine plus brief therapy. Subjects in the first two groups completed significantly more records than did those in the third group (P<0.001). Partial-correlation analysis that controlled for treatment group showed that the more records subjects completed, the more weight they lost at week 18 (r=0.29, P<0.001), week 40 (r=0.22, P=0.01), and week 52 (r=0.31, P<0.001).
The importance of recording food intake was further revealed by examining those in the highest and lowest thirds of adherence in the combined-therapy group and the group treated by lifestyle modification alone. In both groups, subjects in the highest third of adherence lost more than twice as much weight as those in the lowest third of adherence (Figure 3Figure 3
Mean (±SE) Weight Loss at One Year in the Combined-Therapy Group and the Group Treated by Lifestyle Modification Alone among Subjects in the Lowest and Highest Thirds of Adherence for Completing Food-Intake Records during the First 18 Weeks.). Those, for example, in the combined-therapy group who recorded food intake frequently lost more weight than those who did so infrequently (18.1±9.8 kg vs. 7.7±7.5 kg, P=0.04).Serum Chemistry
No significant differences in changes in cardiovascular risk factors were observed among the four groups at any time. Table 2Table 2
Changes in Cardiovascular Risk Factors at Week 52 in the Four Groups, as Determined by a Last-Observation-Carried-Forward Analysis. shows the results for week 52. Combining the four groups, significant reductions were observed in levels of triglycerides (P=0.003), glucose (P<0.001), and insulin and in insulin resistance (P<0.001 for both comparisons). Levels of total cholesterol also declined (P=0.02), whereas HDL cholesterol increased (P=0.003). Partial-correlation analysis that controlled for treatment group showed that weight loss at week 52 was correlated with decreases in triglyceride levels (r=0.31, P<0.001), insulin levels (r=0.28, P<0.001), and insulin resistance (r=0.24, P=0.006) and with increases in HDL cholesterol levels (r=0.26, P=0.004).Blood Pressure and Pulse
At week 18, systolic and diastolic blood pressure both decreased more in the group treated by lifestyle modification alone than in the group given sibutramine alone or the group given sibutramine plus brief therapy (P<0.001 for both comparisons) (Table 3Table 3
Changes in Blood Pressure and Pulse during One Year of Treatment in the Four Groups, as Determined by a Last-Observation-Carried-Forward Analysis.). Diastolic blood pressure increased by approximately 3 mm Hg in the group given sibutramine alone and the group given sibutramine plus brief therapy. At one year, there were no significant differences among groups in the changes in either systolic or diastolic blood pressure. Changes in pulse paralleled changes in blood pressure (Table 3). Partial-correlation analysis that controlled for the treatment group indicated that weight loss at week 52 was correlated with decreases in systolic blood pressure (r=0.33, P<0.001), diastolic blood pressure (r=0.22, P=0.004), and pulse rate (r=0.15, P=0.05).Medication Reduction on the Basis of Cardiovascular Status
Thirty-four subjects taking sibutramine (14 in the group given sibutramine alone, 12 in the combined-therapy group, and 8 in the group given sibutramine plus brief therapy) received reduced doses in response to an increase in systolic or diastolic blood pressure of 10 mm Hg or more above baseline or an increase in the pulse rate of 15 percent or more. These criteria were selected a priori to minimize increases in blood pressure and pulse reported previously with the use of sibutramine.4 Reducing the daily dose from 15 mg to 10 mg typically caused the elevated values to return to baseline.
Adverse Events
Twelve subjects discontinued treatment because of adverse events that included breast cancer, chronic inflammatory polyneuropathy, preexisting attention-deficit disorder treated with bupropion at week 12, hepatitis C, Lyme disease, back injury (in two), heart palpitations, facial rash, and pregnancy (in three, which includes the two women who were excluded from the data analysis). The only adverse events judged to be potentially related to the use of sibutramine were the heart palpitations and facial rash, both of which remitted after withdrawal of the medication. The three full-term pregnancies yielded healthy infants with normal Apgar scores. There were no significant differences among the groups in the rate of adverse events.
Discussion
We found that the combination of group lifestyle-modification counseling and pharmacotherapy resulted in an average loss of 12.1 kg at one year — a loss approximately double that of the groups receiving either sibutramine alone (5.0 kg) or lifestyle-modification counseling alone (6.7 kg). Nearly twice as many subjects in the combined-therapy group as in the monotherapy groups lost 10 percent or more of their initial weight, a prespecified benchmark for success.6 These findings, which are based on all enrollees (not just those who completed treatment), provide strong support for recommendations that weight-loss medications be used only as an adjunct to a comprehensive program of diet, exercise, and behavior therapy.6 These results also confirm previous reports of the benefits of lifestyle modification used alone for inducing clinically and statistically significant weight loss.9,26 Subjects treated by lifestyle modification alone had significantly greater weight loss than those who received sibutramine alone during the first 18 weeks.
We cannot identify the components of group lifestyle modification that contributed most to the increased weight loss when combined with sibutramine therapy. However, keeping daily food-intake records during the first 18 weeks correlated positively with weight loss at all assessments. A secondary analysis showed that subjects in the combined-therapy group who were in the top third of record-keeping lost 18.1 kg, as compared with only 7.7 kg for those in the bottom third. These observations underscore the importance of patients' efforts to modify their eating behavior, rather than relying solely on medication.11,16,23,24
The group given sibutramine plus brief therapy was included to determine whether practitioners might provide effective lifestyle counseling during a limited number of visits of 10 to 15 minutes each, intended to simulate patterns of primary care practice. Subjects in this group lost significantly more weight at week 18 than did those who received sibutramine alone. Thus, it appears that practitioners may be able to provide brief, effective weight-loss counseling. However, the superiority of this approach faded after week 18, when the frequency of visits was reduced.
Treatment with sibutramine plus brief therapy appeared to be as effective in inducing and maintaining weight loss as lifestyle modification alone, which required participation in 30 group sessions of 90 minutes each. Future studies comparing these two therapeutic strategies should include an economic analysis to weigh savings in patients' time and travel against the costs of medication and physicians' visits.27 Studies also must include a thorough evaluation of the status of the patients' general health. At both weeks 18 and 40, we found significant differences between these two groups in changes in systolic and diastolic blood pressure. The difference in diastolic blood pressure was attributable, in part, to a slight rise in blood pressure, as reported previously,4,28,29 in subjects in the group given sibutramine plus brief therapy. These increases were minimized by selectively reducing the dose of sibutramine in 34 subjects from the three groups that included drug therapy. Analysis of other cardiovascular risk factors revealed clinically significant improvements in triglyceride levels and insulin resistance, as estimated by the homeostasis model of insulin sensitivity.30
Our goal was to compare the efficacy of two well-established therapies for obesity — lifestyle modification and pharmacotherapy — and to determine whether the two in combination would be more effective than either treatment alone. We intentionally did not conduct a placebo-controlled trial, since the efficacy of sibutramine has been established in more than a dozen such trials.28 We wished to assess the efficacy of group lifestyle modification alone as customarily delivered. The inclusion of a placebo with this treatment could potentially have undermined subjects' efforts to adhere to diet and exercise recommendations and, thus, limited their weight loss.11,31,32
Our findings strongly suggest that the best weight-loss results will be obtained when medication is used as an adjunct to a comprehensive program of diet, exercise, and behavior therapy. Further research is needed to identify effective methods of providing lifestyle counseling in primary care and community settings.33
Supported by grants (DK56124 and DK065018) from the National Institute of Diabetes and Digestive and Kidney Diseases.
Dr. Wadden reports having received consulting fees from Abbott Laboratories, Merck, Pfizer, and Sanofi-Aventis; lecture fees from GlaxoSmithKline, Roche Laboratories, and Johnson & Johnson; grants from Abbott Laboratories, GlaxoSmithKline, Johnson & Johnson, Merck, and Regeneron; and royalties from American Health Publishing. Dr. Berkowitz reports having received consulting fees from Abbott Laboratories, Johnson & Johnson, Roche Laboratories, Sanofi-Aventis, and Shionogi USA; lecture fees from Abbott Laboratories and Roche Laboratories; and grants from Abbott Laboratories and Knoll Pharmaceutical. Dr. Sarwer reports having received lecture fees from Abbott Laboratories. During the conduct of the study, Dr. Osei worked full time at the University of Pennsylvania but since has moved to GlaxoSmithKline. Dr. Stunkard reports having received grants from Pfizer.
We are indebted to Drs. George Bray and Ken Fujioka for serving as consultants to the study; to Shirley Wang, Rebecca Rothman, and Suzanne MacDonald for their many contributions in coordinating the recruitment, assessment, and treatment of study subjects; and to Johanna Brock for her editorial assistance.
Source Information
From the University of Pennsylvania School of Medicine, Philadelphia (T.A.W., R.I.B., L.G.W., D.B.S., R.K.C., L.A.H., S.Y.O., A.J.S.); the Children's Hospital of Philadelphia, Philadelphia (R.I.B.); Brown Medical School, Providence, R.I. (S.P.); and GlaxoSmithKline, Philadelphia (S.Y.O.) and Bryn Mawr, Pa. (R.K.).
Address reprint requests to Dr. Wadden at the Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market St., Suite 3029, Philadelphia, PA 19104, or at wadden@mail.med.upenn.edu.
- References
References
1
Yanovski SZ ,Yanovski JA . Obesity. N Engl J Med 2002;346:591-602
Full Text | Web of Science | Medline2
Meridia (sibutramine hydrochloride monohydrate). N. Chicago, Ill.: Abbott Laboratories, 2004 (package insert).
3
Xenical (orlistat). Nutley, N.J.: Roche Pharmaceuticals, 1999 (package insert).
4
James WP ,Astrup A ,Finer N , et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-2125
CrossRef | Web of Science | Medline5
Sjostrom L ,Rissanen A ,Andersen T , et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-172
CrossRef | Web of Science | Medline6
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults -- the Evidence Report. Obes Res 1998;6:Suppl 2:51S-209S[Erratum, Obes Res 1998;6:464.]
Medline7
Wadden TA ,Foster GD . Behavioral treatment of obesity. Med Clin North Am 2000;84:441-461
CrossRef | Web of Science | Medline8
Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ, eds. Handbook of obesity treatment. New York: Guilford Press, 2002:301-16.
9
Klein S ,Sheard NF ,Pi-Sunyer X , et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-2073
CrossRef | Web of Science | Medline10
Bray GA ,Ryan DH ,Gordon D ,Heidingsfelder S ,Cerise F ,Wilson K . A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-270
Medline11
Phelan S ,Wadden TA . Combining behavioral and pharmacological treatments for obesity. Obes Res 2002;10:560-574
CrossRef | Medline12
Barkeling B ,Elfhag K ,Rooth P ,Rossner S . Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. Int J Obes Relat Metab Disord 2003;27:693-700
CrossRef | Web of Science | Medline13
Craighead LW ,Stunkard AJ ,O'Brien RM . Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981;38:763-768
Web of Science | Medline14
Craighead LW . Sequencing of behavior therapy and pharmacotherapy for obesity. J Consult Clin Psychol 1984;52:190-199
CrossRef | Web of Science | Medline15
Connolly HM ,Crary JL ,McGoon MD , et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588[Erratum, N Engl J Med 1997;337:1783.]
Full Text | Web of Science | Medline16
Wadden TA ,Berkowitz RI ,Vogt RA ,Steen SN ,Stunkard AJ ,Foster GD . Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res 1997;5:218-226
Medline17
Serdula MK ,Khan LK ,Dietz WH . Weight loss counseling revisited. JAMA 2003;289:1747-1750
CrossRef | Web of Science | Medline18
Haffner SM ,Kennedy E ,Gonzalez C ,Stein MP ,Miettinen H . A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996;19:1138-1141
CrossRef | Web of Science | Medline19
Shape Up America. On your way to fitness. Wilton: Connecticut Marketing Associates, 1996.
20
Brownell KD, ed. The LEARN program for weight control. 7th ed. Dallas: American Health Publishing, 1998.
21
Brownell KD, Rodin J. The weight maintenance survival guide. Dallas: Brownell & Hager, 1990.
22
Brownell KD, Wadden TA. The LEARN program for weight control: special medication edition. Dallas: American Health Publishing, 1999.
23
Berkowitz RI ,Wadden TA ,Tershakovec AM ,Cronquist JL . Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289:1805-1812
CrossRef | Web of Science | Medline24
Wadden TA ,Berkowitz RI ,Sarwer DB ,Prus-Wisniewski R ,Steinberg C . Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001;161:218-227
CrossRef | Web of Science | Medline25
SPSS for Windows, version 11.0. Chicago: SPSS, 2000.
26
Knowler WC ,Barrett-Connor E ,Fowler SE , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
Full Text | Web of Science | Medline27
Avenell A ,Broom J ,Brown TJ , et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182
Web of Science28
Arterburn DE ,Crane PK ,Veenstra DL . The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003
CrossRef | Web of Science | Medline29
Kim SH ,Lee YM ,Jee SH ,Nam CM . Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-1123
CrossRef | Medline30
Wee CC ,Hamel MB ,Davis RB ,Phillips RS . Assessing the value of weight loss among primary care patients. J Gen Intern Med 2004;19:1206-1211
CrossRef | Web of Science | Medline31
Hollon SD ,DeRubeis RJ . Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981;90:467-477
CrossRef | Web of Science | Medline32
Brightwell DR ,Naylor CS . Effects of a combined behavioral and pharmacologic program on weight loss. Int J Obes 1979;3:141-148
Web of Science | Medline33
McTigue KM ,Harris R ,Hemphill B , et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Service Task Force. Ann Intern Med 2003;139:933-949
Web of Science | Medline
- Citing Articles (205)
Citing Articles
1
Nithushi R. Samaranayake, Kwok L. Ong, Raymond Y.H. Leung, Bernard M.Y. Cheung. (2012) Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008. Annals of Epidemiology
CrossRef2
Enrique Morales, Manuel Praga. (2012) The Effect of Weight Loss in Obesity and Chronic Kidney Disease. Current Hypertension Reports
CrossRef3
S Zhao, S E Kanoski, J Yan, H J Grill, M R Hayes. (2012) Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. International Journal of Obesity
CrossRef4
Dao-Fu Dai, Tony Chen, Simon Johnson, Hazel H. Szeto, Peter S. Rabinovitch. (2012) Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease. Antioxidants & Redox Signaling120109141037006
CrossRef5
Simona Moscatiello, Raffaella Di Luzio, Anna Simona Sasdelli, Giulio Marchesini. (2011) Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy 12:17, 2657-2672
CrossRef6
Meghan L. Butryn, Victoria Webb, Thomas A. Wadden. (2011) Behavioral Treatment of Obesity. Psychiatric Clinics of North America 34:4, 841-859
CrossRef7
Polly H. Noël, Chen-Pin Wang, Mary J. Bollinger, Mary J. Pugh, Laurel A. Copeland, Joel Tsevat, Karin M. Nelson, Margaret M. Dundon, Helen P. Hazuda. (2011) Intensity and Duration of Obesity-Related Counseling: Association With 5-Year BMI Trends Among Obese Primary Care Patients. Obesity
CrossRef8
Wadden, Thomas A., Volger, Sheri, Sarwer, David B., Vetter, Marion L., Tsai, Adam G., Berkowitz, Robert I., Kumanyika, Shiriki, Schmitz, Kathryn H., Diewald, Lisa K., Barg, Ronald, Chittams, Jesse, Moore, Reneé H., . (2011) A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice. New England Journal of Medicine 365:21, 1969-1979
Full Text9
Lucy F. Faulconbridge, Thomas A. Wadden, Richard R. Rubin, Rena R. Wing, Michael P. Walkup, Anthony N. Fabricatore, Mace Coday, Brent Van Dorsten, David L. Mount, Linda J. Ewing. (2011) One-Year Changes in Symptoms of Depression and Weight in Overweight/Obese Individuals With Type 2 Diabetes in the Look AHEAD Study. Obesity
CrossRef10
G. Derosa, P. Maffioli, I. Ferrari, I. Palumbo, S. Randazzo, A. D’Angelo, A. F. G. Cicero. (2011) Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. Journal of Clinical Pharmacy and Therapeutics 36:5, 592-601
CrossRef11
Michael Pfeiffer, Rüdiger Bauer, Peter P. Nawroth. (2011) The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. Langenbeck's Archives of Surgery 396:7, 941-947
CrossRef12
Lora E. Burke, Jing Wang. (2011) Treatment Strategies for Overweight and Obesity. Journal of Nursing Scholarshipno-no
CrossRef13
George A. Bray. (2011) Medications for Weight Reduction. Medical Clinics of North America 95:5, 989-1008
CrossRef14
Brent Van Dorsten, Emily M. Lindley. (2011) Cognitive and Behavioral Approaches in the Treatment of Obesity. Medical Clinics of North America 95:5, 971-988
CrossRef15
David B. Sarwer, Rebecca J. Dilks, Lisa West-Smith. (2011) Dietary intake and eating behavior after bariatric surgery: threats to weight loss maintenance and strategies for success. Surgery for Obesity and Related Diseases 7:5, 644-651
CrossRef16
Anita Elaine Weidmann, Scott Cunningham, Gwen Gray, Denise Hansford, James McLay, John Broom, Derek Stewart. (2011) Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain. International Journal of Clinical Pharmacy 33:4, 627-633
CrossRef17
Adam G. Tsai, Sue Felton, James O. Hill, Adam J. Atherly. (2011) A Randomized Pilot Trial of a Full Subsidy vs. a Partial Subsidy for Obesity Treatment. Obesity
CrossRef18
Heather M. Campbell, Nasreen Khan, Catherine Cone, Dennis W. Raisch. (2011) Relationship between diet, exercise habits, and health status among patients with diabetes. Research in Social and Administrative Pharmacy 7:2, 151-161
CrossRef19
Thomas A. Wadden, Lucy F. Faulconbridge, LaShanda R. Jones-Corneille, David B. Sarwer, Anthony N. Fabricatore, J. Graham Thomas, G. Terence Wilson, Madeline G. Alexander, Melissa E. Pulcini, Victoria L. Webb, Noel N. Williams. (2011) Binge Eating Disorder and the Outcome of Bariatric Surgery at One Year: A Prospective, Observational Study. Obesity 19:6, 1220-1228
CrossRef20
T. Rutledge, L. M. Groesz, S. E. Linke, G. Woods, K. L. Herbst. (2011) Behavioural weight management for the primary careprovider. Obesity Reviews 12:5, e290-e297
CrossRef21
G. Osei-Assibey, Y. Adi, I. Kyrou, S. Kumar, K. Matyka. (2011) Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 13:5, 385-393
CrossRef22
Sushama D. Acharya, Okan U. Elci, Susan M. Sereika, Mindi A. Styn, Lora E. Burke. (2011) Using a Personal Digital Assistant for Self-Monitoring Influences Diet Quality in Comparison to a Standard Paper Record among Overweight/Obese Adults. Journal of the American Dietetic Association 111:4, 583-588
CrossRef23
Barham K. Abu Dayyeh, Lee M. Kaplan. (2011) Medical Therapy for Obesity. Gastrointestinal Endoscopy Clinics of North America 21:2, 203-212
CrossRef24
2011. References. , 283-360.
CrossRef25
Giulio Marchesini, Simona Moscatiello, Federica Agostini, Nicola Villanova, Davide Festi. (2011) Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs 16:1, 121-136
CrossRef26
M. Lean. (2011) VLED and formula LED in the management of type 2 diabetes: defining the clinical need and research requirements. Clinical Obesity 1:1, 41-49
CrossRef27
Lora E. Burke, Molly B. Conroy, Susan M. Sereika, Okan U. Elci, Mindi A. Styn, Sushama D. Acharya, Mary A. Sevick, Linda J. Ewing, Karen Glanz. (2011) The Effect of Electronic Self-Monitoring on Weight Loss and Dietary Intake: A Randomized Behavioral Weight Loss Trial. Obesity 19:2, 338-344
CrossRef28
E. Hemmingsson. (2011) Does medically induced weight loss improve obstructive sleep apnoea in the obese: review of randomized trials. Clinical Obesity 1:1, 26-30
CrossRef29
Jens Jordan, Markus Schlaich, Josep Redon, Krzysztof Narkiewicz, Friedrich C Luft, Guido Grassi, John Dixon, Gavin Lambert, Stefan Engeli. (2011) European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. Journal of Hypertension 29:2, 189-193
CrossRef30
Thomas A. Wadden, John P. Foreyt, Gary D. Foster, James O. Hill, Samuel Klein, Patrick M. O'Neil, Michael G. Perri, F. Xavier Pi-Sunyer, Cheryl L. Rock, Janelle S. Erickson, Holly N. Maier, Dennis D. Kim, Eduardo Dunayevich. (2011) Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. Obesity 19:1, 110-120
CrossRef31
Lora E. Burke, Jing Wang, Mary Ann Sevick. (2011) Self-Monitoring in Weight Loss: A Systematic Review of the Literature. Journal of the American Dietetic Association 111:1, 92-102
CrossRef32
Mariela Glandt, Itamar Raz. (2011) Present and Future: Pharmacologic Treatment of Obesity. Journal of Obesity 2011, 1-13
CrossRef33
Antonella Napolitano, Peter R. Murgatroyd, Nick Finer, Elizabeth K. Hussey, Robert Dobbins, Steve O'Rahilly, Derek J. R. Nunez. (2011) Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine. Journal of Obesity 2011, 1-8
CrossRef34
Joong Myung Choi, Chun-Bae Kim. (2011) Obesity management and scientific evidence. Journal of the Korean Medical Association 54:3, 250
CrossRef35
Juan Tur, Maria Alòs, Lourdes Iglesias, Lourdes Luque, Antoni Colom, Antonio Escudero, David Martínez, Alberto Pagán, Elena Ugarriza, Marga Frontera, Gabriela Nicola, Antonio Palomero, Santiago Tofé, Juan Ramón Urgeles, María Antonia Barceló, Marta Couce, Mónica De La Peña, Miguel Fiol, Baltasar Cortés, Emma Terés, Ángela Tumbarello, Cristina Álvarez, Ramón Salinas, Vicente Pereg, Xavier González, Bartolomé Burguera. (2011) TRAMOMTANA (Multidisciplinary treatment of morbid obesity: Medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II). Endocrinología y Nutrición (English Edition) 58:6, 299-307
CrossRef36
Thomas A. Wadden, Ken Fujioka, Soren Toubro, Ira Gantz, Ngozi E. Erondu, Menghui Chen, Shailaja Suryawanshi, Wendy Carofano, Amy O. Johnson-Levonas, Deborah R. Shapiro, Keith D. Kaufman, Steven B. Heymsfield, John M. Amatruda. (2010) A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet. Obesity 18:12, 2301-2310
CrossRef37
Richard B Rothman. (2010) Treatment of Obesity With “Combination” Pharmacotherapy. American Journal of Therapeutics 17:6, 596-603
CrossRef38
K. Johansson, J. Sundström, K. Neovius, S. Rössner, M. Neovius. (2010) Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obesity Reviews 11:11, 777-791
CrossRef39
F. Hanzu, R. Gomis, M. J. Coves, J. Viaplana, M. Palomo, A. Andreu, J. Szpunar, J. Vidal. (2010) Proof-of-concept trial on the efficacy of sodium tungstate in human obesity. Diabetes, Obesity and Metabolism 12:11, 1013-1018
CrossRef40
L. O. Reis, W. J. Favaro, G. C. Barreiro, L. C. De Oliveira, E. A. Chaim, A. Fregonesi, U. Ferreira. (2010) Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. International Journal of Andrology 33:5, 736-744
CrossRef41
Nayyar Iqbal, Marion L. Vetter, Reneé H. Moore, Jesse L. Chittams, Cornelia V. Dalton-Bakes, Monique Dowd, Catherine Williams-Smith, Serena Cardillo, Thomas A. Wadden. (2010) Effects of a Low-intensity Intervention That Prescribed a Low-carbohydrate vs. a Low-fat Diet in Obese, Diabetic Participants. Obesity 18:9, 1733-1738
CrossRef42
Lisa M. Nackers, Kathryn M. Ross, Michael G. Perri. (2010) The Association Between Rate of Initial Weight Loss and Long-Term Success in Obesity Treatment: Does Slow and Steady Win the Race?. International Journal of Behavioral Medicine 17:3, 161-167
CrossRef43
G. Terence Wilson. (2010) Eating disorders, obesity and addiction. European Eating Disorders Review 18:5, 341-351
CrossRef44
George A. Bray. (2010) Medical Therapy for Obesity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 407-417
CrossRef45
Shelby Sullivan. 2010. Weight Management Strategies. , 315-326.
CrossRef46
Marion L. Vetter, Lucy F. Faulconbridge, Victoria L. Webb, Thomas A. Wadden. (2010) Behavioral and pharmacologic therapies for obesity. Nature Reviews Endocrinology
CrossRef47
Tiffany M. Powell, Amit Khera. (2010) Therapeutic Approaches to Obesity. Current Treatment Options in Cardiovascular Medicine 12:4, 381-395
CrossRef48
Halil Coskun, Ozgur Bostanci. (2010) Assessment of the Application of the Intragastric Balloon Together with Sibutramine: A Prospective Clinical Study. Obesity Surgery 20:8, 1117-1120
CrossRef49
Donald E. McAlpine, Maria J. Frisch, Ellen S. Rome, Matthew M. Clark, Carol Signore, Anna Karin Lindroos, Kelly C. Allison. (2010) Bariatric surgery: A primer for eating disorder professionals. European Eating Disorders Review 18:4, 304-317
CrossRef50
Chizuko Maruyama, Mika Kimura, Hisashi Okumura, Kenji Hayashi, Takashi Arao. (2010) Effect of a worksite-based intervention program on metabolic parameters in middle-aged male white-collar workers: A randomized controlled trial. Preventive Medicine 51:1, 11-17
CrossRef51
David G. Blackburn, Kristina D. Spellman. (2010) The Role of Internet Technology in Enhancing the Effectiveness of Lifestyle Interventions for Weight Management. Obesity and Weight Management 6:3, 131-135
CrossRef52
Sévrine Buclin-Thiébaud, Zoltan Pataky, Vanessa Bruchez, Alain Golay. (2010) New psycho-pedagogic approach to obesity treatment: A 5-year follow-up. Patient Education and Counseling 79:3, 333-337
CrossRef53
Henrik H. Hansen, Gitte Hansen, Mads Tang-Christensen, Philip J. Larsen, Anne Marie D. Axel, Anne Raben, Jens D. Mikkelsen. (2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. European Journal of Pharmacology 636:1-3, 88-95
CrossRef54
Ian Caterson, Walmir Coutinho, Nick Finer, Luc Van Gaal, Aldo Maggioni, Christian Torp-Pedersen, Arya M. Sharma, Hong Ge, Donatella Santoro, Gillian Shepherd, Philip James. (2010) Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period. Obesity 18:5, 987-994
CrossRef55
Giovanni Targher, Alessandro Bellis, Paolo Fornengo, Francesca Ciaravella, Isabella Pichiri, Paolo Cavallo Perin, Bruno Trimarco, Giulio Marchesini. (2010) Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease 42:5, 331-340
CrossRef56
Nora Straznicky, Guido Grassi, Murray Esler, Gavin Lambert, John Dixon, Elisabeth Lambert, Jens Jordan, Markus Schlaich. (2010) European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?. Journal of Hypertension 28:4, 637-643
CrossRef57
M. Reiser, S. Eickmann, T. Haverkamp, U. Finckh. (2010) Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss. Obesity Reviews 11:4, 329-331
CrossRef58
A. B. Motta. (2010) Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. International Journal of Clinical Practice 64:5, 544-557
CrossRef59
Lee M. Kaplan. (2010) Pharmacologic Therapies for Obesity. Gastroenterology Clinics of North America 39:1, 69-79
CrossRef60
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef61
Michael G. Perri, Lisa M. Nackers. 2010. Obesity. .
CrossRef62
Meghan L. Butryn, Thomas A. Wadden, Margaret R. Rukstalis, Chanelle Bishop-Gilyard, Melissa S. Xanthopoulos, Delroy Louden, Robert I. Berkowitz. (2010) Maintenance of Weight Loss in Adolescents: Current Status and Future Directions. Journal of Obesity 2010, 1-12
CrossRef63
Shilpi Pandey, Siladitya Bhattacharya. (2010) Impact of obesity on gynecology. Women's Health 6:1, 107-117
CrossRef64
Joong Kyung Sung, Jang-Young Kim. (2010) Obesity and Preclinical Changes of Cardiac Geometry and Function. Korean Circulation Journal 40:2, 55
CrossRef65
Ivana Tadic, Ljiljana Tasic, Brizita Djordjevic, Tatjana Kundakovic, Milan Rakic, Natasa Bogavac-Stanojevic. (2010) Analysis of the consumption of dietary supplements for weight loss. Vojnosanitetski pregled 67:10, 831-838
CrossRef66
Joseph Yaskin, Richard W. Toner, Neil Goldfarb. (2009) Obesity Management Interventions: A Review of the Evidence. Population Health Management 12:6, 305-316
CrossRef67
Mingfang Li, Bernard M. Y. Cheung. (2009) Pharmacotherapy for obesity. British Journal of Clinical Pharmacology 68:6, 804-810
CrossRef68
Lalita Khaodhiar, Sue Cummings, Caroline M. Apovian. (2009) Treating diabetes and prediabetes by focusing on obesity management. Current Diabetes Reports 9:5, 348-354
CrossRef69
Jeffrey Derbas, Marion Vetter, Sheri Volger, Zahra Khan, Eva Panigrahi, Adam G. Tsai, David B. Sarwer, Thomas A. Wadden. (2009) Improving Weight Management in Primary Care Practice: A Possible Role for Auxiliary Health Professionals Collaborating with Primary Care Physicians. Obesity and Weight Management 5:5, 210-215
CrossRef70
David B Sarwer, Amy von Sydow Green, Marion L Vetter, Thomas A Wadden. (2009) Behavior therapy for obesity: where are we now?. Current Opinion in Endocrinology, Diabetes and Obesity 16:5, 347-352
CrossRef71
Adam Gilden Tsai, Thomas A. Wadden. (2009) Treatment of Obesity in Primary Care Practice in the United States: A Systematic Review. Journal of General Internal Medicine 24:9, 1073-1079
CrossRef72
K. Johansson, K. Neovius, S. M. DeSantis, S. Rössner, M. Neovius. (2009) Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Reviews 10:5, 564-575
CrossRef73
George A. Bray. (2009) Medications for Obesity: Mechanisms and Applications. Clinics in Chest Medicine 30:3, 525-538
CrossRef74
Carole N. Kamga-Ngandé, André C. Carpentier, Frédérique Nadeau-Marcotte, Jean-Luc Ardilouze, Jean-Patrice Baillargeon, Diego Bellabarba, Ghislaine Houde, Marie-France Langlois. (2009) Effectiveness of a Multidisciplinary Program for Management of Obesity: The Unité d’Enseignement, de Traitement et de Recherche sur l’Obésité (UETRO) Database Study. Metabolic Syndrome and Related Disorders 7:4, 297-304
CrossRef75
Anthony N. Fabricatore, Thomas A. Wadden, Reneé H. Moore, Meghan L. Butryn, Steven B. Heymsfield, Allison Martin Nguyen. (2009) Predictors of attrition and weight loss success: Results from a randomized controlled trial. Behaviour Research and Therapy 47:8, 685-691
CrossRef76
Richard B Rothman, Michael H Baumann. (2009) Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. American Journal of Therapeutics 16:4, 354-364
CrossRef77
J. Ricardo Loret de Mola. (2009) Obesity and Its Relationship to Infertility in Men and Women. Obstetrics and Gynecology Clinics of North America 36:2, 333-346
CrossRef78
Lisa J Miller. (2009) Management of Atypical Antipsychotic Drug–Induced Weight Gain: Focus on Metformin. Pharmacotherapy 29:6, 725-735
CrossRef79
István Barna. (2009) A prediabéteszhez társult hypertonia kezelése. Orvosi Hetilap 150:20, 917-923
CrossRef80
A. N. Fabricatore, T. A. Wadden, R. H. Moore, M. L. Butryn, E. A. Gravallese, N. E. Erondu, S. B. Heymsfield, A. M. Nguyen. (2009) Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obesity Reviews 10:3, 333-341
CrossRef81
Jerrilynn D. Burrowes. (2009) Treating Obesity in Chronic Kidney Disease. Nutrition Today 44:3, 118-123
CrossRef82
Lucy F. Faulconbridge, Thomas A. Wadden, Robert I. Berkowitz, David B. Sarwer, Leslie G. Womble, Louise A. Hesson, Albert J. Stunkard, Anthony N. Fabricatore. (2009) Changes in Symptoms of Depression With Weight Loss: Results of a Randomized Trial. Obesity 17:5, 1009-1016
CrossRef83
Laura E. Shay, Jennifer L. Shobert, Diane Seibert, Lauren E. Thomas. (2009) Adult weight management: Translating research and guidelines into practice. Journal of the American Academy of Nurse Practitioners 21:4, 197-206
CrossRef84
John B. Dixon, Cheryl P. Laurie, Margaret L. Anderson, Melissa J. Hayden, Maureen E. Dixon, Paul E. O'Brien. (2009) Motivation, Readiness to Change, and Weight Loss Following Adjustable Gastric Band Surgery. Obesity 17:4, 698-705
CrossRef85
Maya Lottati, Cathryn M. Kolka, Darko Stefanovski, Erlinda L. Kirkman, Richard N. Bergman. (2009) Greater Omentectomy Improves Insulin Sensitivity in Nonobese Dogs. Obesity 17:4, 674-680
CrossRef86
Roger Kirby, Peter Amoroso, Michael Kirby. (2009) MORE PRO-ACTIVITY IS REQUIRED IN THE BATTLE AGAINST OBESITY IN MEN. BJU International 103:8, 1019-1020
CrossRef87
Jeff K. Vallance, Mark Wylie, Randy MacDonald. (2009) Medical students' self-perceived competence and prescription of patient-centered physical activity. Preventive Medicine 48:2, 164-166
CrossRef88
JOSEPH E. DONNELLY, STEVEN N. BLAIR, JOHN M. JAKICIC, MELINDA M. MANORE, JANET W. RANKIN, BRYAN K. SMITH. (2009) Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults. Medicine & Science in Sports & Exercise 41:2, 459-471
CrossRef89
(2009) Position of the American Dietetic Association: Weight Management. Journal of the American Dietetic Association 109:2, 330-346
CrossRef90
Kristin A. Harmon, Daniel H. Bessesen. 2009. Obesity. , 76-88.
CrossRef91
D. Sánchez Fuentes, M. Budiño Sánchez. (2008) Síndrome metabólico. Medicine - Programa de Formación Médica Continuada Acreditado 10:23, 1527-1533
CrossRef92
Ramsey M. Dallal, Arthur Chernoff, Michael P. O'Leary, Jason A. Smith, Justin D. Braverman, Brian B. Quebbemann. (2008) Sexual Dysfunction Is Common in the Morbidly Obese Male and Improves after Gastric Bypass Surgery. Journal of the American College of Surgeons 207:6, 859-864
CrossRef93
James E. Rohrer, Paul Takahashi. (2008) Should overweight and obese primary care patients be offered a meal replacement diet?. Obesity Research & Clinical Practice 2:4, 263-268
CrossRef94
George A. Bray. (2008) Medications for Weight Reduction. Endocrinology & Metabolism Clinics of North America 37:4, 923-942
CrossRef95
Brent Van Dorsten, Emily M. Lindley. (2008) Cognitive and Behavioral Approaches in the Treatment of Obesity. Endocrinology & Metabolism Clinics of North America 37:4, 905-922
CrossRef96
Sarah L. Teegarden, Eric J. Nestler, Tracy L. Bale. (2008) ΔFosB-Mediated Alterations in Dopamine Signaling Are Normalized by a Palatable High-Fat Diet. Biological Psychiatry 64:11, 941-950
CrossRef97
(2008) Obesity and reproduction: an educational bulletin. Fertility and Sterility 90:5, S21-S29
CrossRef98
Angela Marinilli Pinto, Amy A. Gorin, Hollie A. Raynor, Deborah F. Tate, Joseph L. Fava, Rena R. Wing. (2008) Successful Weight-loss Maintenance in Relation to Method of Weight Loss. Obesity 16:11, 2456-2461
CrossRef99
A.E. Nieuwenhuis-Ruifrok, W.K.H. Kuchenbecker, A. Hoek, P. Middleton, R.J. Norman. (2008) Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Human Reproduction Update 15:1, 57-68
CrossRef100
April B.M. Grudell, Seth Sweetser, Michael Camilleri, Deborah J. Eckert, Maria I. Vazquez-Roque, Paula J. Carlson, Duane D. Burton, Autumn E. Braddock, Matthew M. Clark, Karen M. Graszer, Sarah A. Kalsy, Alan R. Zinsmeister. (2008) A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. Gastroenterology 135:4, 1142-1154
CrossRef101
Ellen Chen, Thomas Bodenheimer. (2008) Applying the Chronic Care Model to the Management of Obesity. Obesity Management 4:5, 227-231
CrossRef102
M. Tiburcy, W.-H. Zimmermann. (2008) Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen. Der Kardiologe 2:5, 417-429
CrossRef103
C. Lloret-Linares, J. R. Greenfield, S. Czernichow. (2008) Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. Diabetic Medicine 25:10, 1142-1150
CrossRef104
H. Hauner, W. Herzog. (2008) Ernährungsmedizinische und psychosomatische Aspekte der Adipositas. Der Chirurg 79:9, 819-825
CrossRef105
Philip Roudebush, William D. Schoenherr, Sean J. Delaney. (2008) An evidence-based review of the use of therapeutic foods, owner education, exercise, and drugs for the management of obese and overweight pets. Journal of the American Veterinary Medical Association 233:5, 717-725
CrossRef106
A.N. Schüring, K. Oelmeier, N. Schulte, P. Stute, L. Kiesel. (2008) Konsensusgerechte Therapie des PCOS. Gynäkologische Endokrinologie 6:3, 185-194
CrossRef107
E. J. Bryant, N. A. King, J. E. Blundell. (2008) Disinhibition: its effects on appetite and weight regulation. Obesity Reviews 9:5, 409-419
CrossRef108
Mary-Ellen Harper, Katherine Green, Martin D. Brand. (2008) The Efficiency of Cellular Energy Transduction and Its Implications for Obesity. Annual Review of Nutrition 28:1, 13-33
CrossRef109
Bikash Sharma, David C Henderson. (2008) Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opinion on Pharmacotherapy 9:12, 2161-2173
CrossRef110
A. Hamann, J. Tafel. (2008) Nutzen und Risiko der medikamentösen Adipositastherapie. Der Diabetologe 4:4, 266-271
CrossRef111
Arya M Sharma. (2008) The value of current interventions for obesity. Nature Clinical Practice Cardiovascular Medicine 5, S3-S9
CrossRef112
Giovanni de Simone, Gianpaolo D'Addeo. (2008) Sibutramine: Balancing weight loss benefit and possible cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases 18:5, 337-341
CrossRef113
Juan José Rodríguez Cristóbal, Carlos Alonso-Villaverde Grote, Ferran Flor Serra, Pere Travé Mercadé, José M. Pérez Santos, Esther Peña Sendra. (2008) Ensayo clínico de intervención en pacientes con hiperfibrinogenemia en prevención primaria de enfermedad cardiovascular en el ámbito de la atención primaria de salud. Clínica e Investigación en Arteriosclerosis 20:3, 102-109
CrossRef114
Shahla Nader. (2008) Treatment for polycystic ovary syndrome: a critical appraisal of treatment options. Expert Review of Endocrinology & Metabolism 3:3, 349-359
CrossRef115
C. Simon. (2008) Adult obesity and diet. InnovAiT 1:5, 387-395
CrossRef116
Kathy Keenan Isoldi, Louis J. Aronne. (2008) The Challenge of Treating Obesity: The Endocannabinoid System as a Potential Target. Journal of the American Dietetic Association 108:5, 823-831
CrossRef117
Åsa Lindholm, Marie Bixo, Inger Björn, Pål Wölner-Hanssen, Mats Eliasson, Anders Larsson, Owe Johnson, Inger Sundström Poromaa. (2008) Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility 89:5, 1221-1228
CrossRef118
Eckel, Robert H., . (2008) Nonsurgical Management of Obesity in Adults. New England Journal of Medicine 358:18, 1941-1950
Full Text119
Cathy Nonas, Jennifer Williams, Valentine J Burroughs. 2008. Methods of Weight Control. , 31-54.
CrossRef120
Marta Cobo Martín, Pedro Fernández Gil, Javier Crespo. (2008) Tratamiento de la enfermedad hepática por depósito de grasa. Gastroenterología y Hepatología 31:4, 229-238
CrossRef121
Mark Topazian, Michael Camilleri, Jose Mora-Levy, Felicity B. Enders, Amy E. Foxx-Orenstein, Michael J. Levy, Vandana Nehra, Nicholas J. Talley. (2008) Endoscopic Ultrasound-Guided Gastric Botulinum Toxin Injections in Obese Subjects: A Pilot Study. Obesity Surgery 18:4, 401-407
CrossRef122
(2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertility and Sterility 89:3, 505-522
CrossRef123
Susan M. Schwartz, Vidhu P. Bansal, Cecilia Hale, Maureen Rossi, Janet P. Engle. (2008) Compliance, Behavior Change, and Weight Loss With Orlistat in an Over-the-Counter Setting. Obesity 16:3, 623-629
CrossRef124
Lora E. Burke, Susan M. Sereika, Edvin Music, Melanie Warziski, Mindi A. Styn, Arthur Stone. (2008) Using instrumented paper diaries to document self-monitoring patterns in weight loss. Contemporary Clinical Trials 29:2, 182-193
CrossRef125
André J Scheen. (2008) The future of obesity: new drugs versus lifestyle interventions. Expert Opinion on Investigational Drugs 17:3, 263-267
CrossRef126
C A Befort, E E Stewart, B K Smith, C A Gibson, D K Sullivan, J E Donnelly. (2008) Weight maintenance, behaviors and barriers among previous participants of a university-based weight control program. International Journal of Obesity 32:3, 519-526
CrossRef127
Harold E Bays, J Michael González-Campoy, George A Bray, Abbas E Kitabchi, Donald A Bergman, Alan Bruce Schorr, Helena W Rodbard, Robert R Henry. (2008) Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Review of Cardiovascular Therapy 6:3, 343-368
CrossRef128
Melanie T. Warziski, Susan M. Sereika, Mindi A. Styn, Edvin Music, Lora E. Burke. (2008) Changes in self-efficacy and dietary adherence: the impact on weight loss in the PREFER study. Journal of Behavioral Medicine 31:1, 81-92
CrossRef129
Wai Ping Alicia Chan, Aaron Leonid Sverdlov, John David Horowitz. (2008) Management of the metabolic syndrome in cardiovascular disease. Current Treatment Options in Cardiovascular Medicine 10:1, 27-38
CrossRef130
D.J. Heal, S.L. Smith, A. Fisas, X. Codony, H. Buschmann. (2008) Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacology & Therapeutics 117:2, 207-231
CrossRef131
Adam Gilden Tsai, Thomas A Wadden, David B Sarwer, Robert I Berkowitz, Leslie G Womble, Louise A Hesson, Suzanne Phelan, Rebecca Rothman. (2008) Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction. Obesity 16:1, 59-63
CrossRef132
A. Hamann. (2008) Pharmakotherapie der Adipositas. Der Internist 49:1, 106-113
CrossRef133
Stefan Knecht, Tanja Ellger, James A. Levine. (2008) Obesity in neurobiology. Progress in Neurobiology 84:1, 85-103
CrossRef134
Robert Nicholson, Marcelo Bigal. (2008) Screening and Behavioral Management: Obesity and Weight Management. Headache: The Journal of Head and Face Pain 48:1, 51-57
CrossRef135
James E Rohrer, Harvey D Cassidy, Diane Dressel, Barbara Cramer. (2008) Effectiveness of a Structured Intensive Weight Loss Program Using Health Educators. Disease Management & Health Outcomes 16:6, 449-454
CrossRef136
R. P. Vincent, C. W. Le Roux. (2007) New agents in development for the management of obesity. International Journal of Clinical Practice 61:12, 2103-2112
CrossRef137
On-Anong Waleekhachonloet, Chulaporn Limwattananon, Supon Limwattananon, Cynthia R. Gross. (2007) Group behavior therapy versus individual behavior therapy for healthy dieting and weight control management in overweight and obese women living in rural community. Obesity Research & Clinical Practice 1:4, 223-232
CrossRef138
Mauro Cignarelli, Olga Lamacchia. (2007) Obesity and kidney disease. Nutrition, Metabolism and Cardiovascular Diseases 17:10, 757-762
CrossRef139
Amy A. Gorin, Angela Marinilli Pinto, Deborah F. Tate, Hollie A. Raynor, Joseph L. Fava, Rena R. Wing. (2007) Failure to Meet Weight Loss Expectations Does Not Impact Maintenance in Successful Weight Losers**. Obesity 15:12, 3086-3090
CrossRef140
Louis J. Aronne, W. Virgil Brown, Kathy Keenan Isoldi. (2007) Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies. Journal of Clinical Lipidology 1:6, 575-582
CrossRef141
J A Batsis, R E Nieto-Martinez, F Lopez-Jimenez. (2007) Metabolic Syndrome: From Global Epidemiology to Individualized Medicine. Clinical Pharmacology & Therapeutics 82:5, 509-524
CrossRef142
A N Fabricatore, T A Wadden, L G Womble, D B Sarwer, R I Berkowitz, G D Foster, J R Brock. (2007) The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity. International Journal of Obesity 31:11, 1739-1745
CrossRef143
George A. Bray. (2007) Medical Therapy for Obesity—Current Status and Future Hopes. Medical Clinics of North America 91:6, 1225-1253
CrossRef144
Jing Chen, Raymond R Townsend. (2007) Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. Expert Opinion on Pharmacotherapy 8:13, 2001-2009
CrossRef145
Michael Vogeser, Daniel König, Ingrid Frey, Hans-Georg Predel, Klaus Georg Parhofer, Aloys Berg. (2007) Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clinical Biochemistry 40:13-14, 964-968
CrossRef146
S Phelan, T A Wadden, R I Berkowitz, D B Sarwer, L G Womble, R K Cato, R Rothman. (2007) Impact of weight loss on the metabolic syndrome. International Journal of Obesity 31:9, 1442-1448
CrossRef147
Alejandra Larrañaga, Ricardo García-Mayor. (2007) Tratamiento psicológico de la obesidad. Medicina Clínica 129:10, 387-391
CrossRef148
Scott M Nelson, Richard Fleming. (2007) Obesity and reproduction: impact and interventions. Current Opinion in Obstetrics and Gynecology 19:4, 384-389
CrossRef149
Maria I. Vazquez Roque, Michael Camilleri, Matthew M. Clark, Debra A. TePoel, Michael D. Jensen, Karen M. Graszer, Sarah A. Kalsy, Duane D. Burton, Kari L. Baxter, Alan R. Zinsmeister. (2007) Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine. Clinical Gastroenterology and Hepatology 5:7, 829-837
CrossRef150
Cheryl Sterling Lynch, Judy C. Chang, Angela F. Ford, Said A. Ibrahim. (2007) Obese African-American Women’s Perspectives on Weight Loss and Bariatric Surgery. Journal of General Internal Medicine 22:7, 908-914
CrossRef151
(2007) Treatment of Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine 356:19, 1999-2001
Full Text152
Elizabeth M. Venditti. (2007) Efficacy of lifestyle behavior change programs in diabetes. Current Diabetes Reports 7:2, 123-127
CrossRef153
m. camilleri, a. b. m. grudell. (2007) Appetite and obesity: a gastroenterologist's perspective. Neurogastroenterology & Motility 19:5, 333-341
CrossRef154
J. Gille, J. Aberle, P. Busch, O. Mann, M. Faschingbauer, C. Jürgens. (2007) Dicke Chance – die operative Behandlung der schweren Adipositas bei posttraumatischer Osteoarthrose. Der Unfallchirurg 110:5, 450-455
CrossRef155
George A. Bray, Donna H. Ryan. (2007) Drug Treatment of the Overweight Patient. Gastroenterology 132:6, 2239-2252
CrossRef156
S.A. Ritchie, J.M.C. Connell. (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 17:4, 319-326
CrossRef157
L R Jones, C I Wilson, T A Wadden. (2007) Lifestyle Modification in the Treatment of Obesity: An Educational Challenge and Opportunity. Clinical Pharmacology & Therapeutics 81:5, 776-779
CrossRef158
N I Hutchinson, S W Ryder. (2007) Obesity Pharmacotherapy from a Regulatory Perspective: Overview and Key Challenges. Clinical Pharmacology & Therapeutics 81:5, 756-760
CrossRef159
Thomas A. Wadden, Meghan L. Butryn, Christopher Wilson. (2007) Lifestyle Modification for the Management of Obesity. Gastroenterology 132:6, 2226-2238
CrossRef160
Alicia R. Ruelaz, Pamela Diefenbach, Barbara Simon, Andy Lanto, David Arterburn, Paul G. Shekelle. (2007) Perceived Barriers to Weight Management in Primary Care—Perspectives of Patients and Providers. Journal of General Internal Medicine 22:4, 518-522
CrossRef161
A. de la Peña Fernández, B. Roca Villanueva, I. Cuende Melero, J.R. Calabuig Alborch, J. Montes Santiago, M. Muñoz Rodríguez, M. Piedracausa Selfa, C. Suárez Fernández. (2007) Efecto de una intervención global sobre el control integral de múltiples factores de riesgo en pacientes con alto o muy alto riesgo cardiovascular. Estudio CIFARC 2. Revista Clínica Española 207:3, 112-120
CrossRef162
Marion J. Franz. (2007) The role of nutrition therapy and dietitians in the management of the metabolic syndrome. Current Diabetes Reports 7:1, 60-65
CrossRef163
Robert F. Kushner. (2007) Obesity Management. Gastroenterology Clinics of North America 36:1, 191-210
CrossRef164
KATHLEEN M. HOEGER. (2007) Obesity and Lifestyle Management in Polycystic Ovary Syndrome. Clinical Obstetrics and Gynecology 50:1, 277-294
CrossRef165
Tore Christiansen, Jens M. Bruun, Erik L. Madsen, Bjørn Richelsen. (2007) Weight Loss Maintenance in Severely Obese Adults after an Intensive Lifestyle Intervention: 2- to 4-Year Follow-Up*. Obesity 15:2, 413-420
CrossRef166
Karl G. Hofbauer, Janet R. Nicholson, Olivier Boss. (2007) The Obesity Epidemic: Current and Future Pharmacological Treatments. Annual Review of Pharmacology and Toxicology 47:1, 565-592
CrossRef167
Torsten Lauritzen, Knut Borch-Johnsen, Annelli Sandbæk. (2007) Is prevention of Type-2 diabetes feasible and efficient in primary care?. Primary Care Diabetes 1:1, 5-11
CrossRef168
Jordi Salas-Salvadó, Miguel A. Rubio, Montserrat Barbany, Basilio Moreno. (2007) Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Medicina Clínica 128:5, 184-196
CrossRef169
Michelle Lee, Louis J. Aronne. (2007) Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction. The American Journal of Cardiology 99:4, 68-79
CrossRef170
Anthony N. Fabricatore. (2007) Behavior Therapy and Cognitive-Behavioral Therapy of Obesity: Is There a Difference?. Journal of the American Dietetic Association 107:1, 92-99
CrossRef171
Raj S Padwal, Sumit R Majumdar. (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet 369:9555, 71-77
CrossRef172
Gary Wittert, Ian Caterson, Nick Finer. (2007) The clinical effectiveness of weight loss drugs. Obesity Research & Clinical Practice 1:1, 1-5
CrossRef173
G.L. Moneta. (2007) Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. Yearbook of Vascular Surgery 2007, 84-86
CrossRef174
Antonio Gil-Núñez. (2007) The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence. Cerebrovascular Diseases 24:1, 64-75
CrossRef175
Warren G. Thompson, David A. Cook, Matthew M. Clark, Aditya Bardia, James A. Levine. (2007) Treatment of Obesity. Mayo Clinic Proceedings 82:1, 93-102
CrossRef176
W. G. Thompson, D. A. Cook, M. M. Clark, A. Bardia, J. A. Levine. (2007) Treatment of Obesity. Mayo Clinic Proceedings 82:1, 93-102
CrossRef177
Elizabeth E Roughead. (2006) Enhancing early uptake of drug evidence into primary care. Expert Review of Pharmacoeconomics & Outcomes Research 6:6, 661-671
CrossRef178
Michael Bottorff. (2006) Role of the Pharmacist. Pharmacotherapy 26:12part2, 227S-232S
CrossRef179
Paul M Copeland. (2006) How successful are commercial weight-loss programs?. Nature Clinical Practice Endocrinology & Metabolism 2:12, 658-659
CrossRef180
A. S. WIERZBICKI. (2006) Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International Journal of Clinical Practice 60:12, 1697-1706
CrossRef181
Angela D. Gray, Michael L. Power, Stanley Zinberg, Jay Schulkin. (2006) Assessment and Management of Obesity. Obstetrical & Gynecological Survey 61:11, 742-748
CrossRef182
Wing, Rena R., Tate, Deborah F., Gorin, Amy A., Raynor, Hollie A., Fava, Joseph L., . (2006) A Self-Regulation Program for Maintenance of Weight Loss. New England Journal of Medicine 355:15, 1563-1571
Full Text183
W. S. C. POSTON, C. K. HADDOCK, M. M. PINKSTON, P. PACE, R. S. REEVES, N. KARAKOC, P. JONES, J. P. FOREYT. (2006) Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. Journal of Internal Medicine 260:4, 388-398
CrossRef184
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef185
Eve A. Roberts, Jason Yap. (2006) Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient. Current Treatment Options in Gastroenterology 9:5, 423-431
CrossRef186
Herman Blomeier, Neil J Stone. 2006. Obesity and Lifestyle Modification. , 63-78.
CrossRef187
Lewis H. Kuller, Laura S. Kinzel, Kelley K. Pettee, Andrea M. Kriska, Laurey R. Simkin-Silverman, Molly B. Conroy, Frani Averbach, W. Scott Pappert, B. Delia Johnson. (2006) Lifestyle Intervention and Coronary Heart Disease Risk Factor Changes over 18 Months in Postmenopausal Women: The Women On the Move through Activity And Nutrition (WOMAN Study) Clinical Trial. Journal of Women's Health 15:8, 962-974
CrossRef188
T. L. Yap, C. T. Brown, M. Emberton. (2006) Self-management in lower urinary tract symptoms: the next major therapeutic revolution. World Journal of Urology 24:4, 371-377
CrossRef189
Manuel Praga, Enrique Morales. (2006) Obesity, proteinuria and progression of renal failure. Current Opinion in Nephrology and Hypertension 15:5, 481-486
CrossRef190
Kerri L. Palamara, Harriette R. Mogul, Stephen J. Peterson, William H. Frishman. (2006) Obesity. Cardiology in Review 14:5, 238-258
CrossRef191
Adam Gilden Tsai, Thomas A. Wadden. (2006) The Evolution of Very-Low-Calorie Diets: An Update and Meta-analysis*. Obesity 14:8, 1283-1293
CrossRef192
John F. Pohl, Matthew Stephen, Don P. Wilson. (2006) Pediatric Obesity: Impact and Surgical Management. Southern Medical Journal 99:8, 833-844
CrossRef193
Anuja Dokras, Lindsey Baredziak, Jill Blaine, Craig Syrop, Bradley J. VanVoorhis, Amy Sparks. (2006) Obstetric Outcomes After In Vitro Fertilization in Obese and Morbidly Obese Women. Obstetrics & Gynecology 108:1, 61-69
CrossRef194
Agnieszka Behn, Ehud Ur. (2006) The obesity epidemic and its cardiovascular consequences. Current Opinion in Cardiology 21:4, 353-360
CrossRef195
John E. Gerich, Hans J. Woerle. (2006) Clinical significance of postprandial hyperglycemia. Drug Development Research 67:7, 587-590
CrossRef196
Gary D. Foster. (2006) Clinical Implications for the Treatment of Obesity. Obesity 14:7S, S182-S185
CrossRef197
P RUTKOWSKI, A KLASSEN, K SEBEKOVA, U BAHNER, A HEIDLAND. (2006) Renal Disease in Obesity: The Need for Greater Attention. Journal of Renal Nutrition 16:3, 216-223
CrossRef198
Kathleen M. Hoeger. (2006) Role of lifestyle modification in the management of polycystic ovary syndrome. Best Practice & Research Clinical Endocrinology & Metabolism 20:2, 293-310
CrossRef199
F. Xavier Pi-Sunyer. (2006) Use of Lifestyle Changes Treatment Plans and Drug Therapy in Controlling Cardiovascular and Metabolic Risk Factors. Obesity 14:6s, 135S-142S
CrossRef200
Susan Z Yanovski. (2006) Can we predict treatment response to antiobesity medication?. Nature Clinical Practice Endocrinology & Metabolism 2:6, 314-315
CrossRef201
(2006) The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It*. Obesity 14:5, 737-752
CrossRef202
Mary Ann Banerji, Mustafa Tiewala. (2006) Clinical trials report. Current Diabetes Reports 6:3, 227-229
CrossRef203
D BESSESEN. (2006) Randomized Trial of Lifestyle Modification and Pharmacotherapy for ObesityWadden TA, Berkowitz RI, Womble LG, et al (Univ of Pennsylvania, Philadelphia; Children's Hosp of Philadelphia; Brown Med School, Providence, RI; et al) N Engl J Med 353:2111–2120, 2005§. Yearbook of Endocrinology 2006, 161-164
CrossRef204
Yanovski, Susan Z., . (2005) Pharmacotherapy for Obesity — Promise and Uncertainty. New England Journal of Medicine 353:20, 2187-2189
Full Text205
Raj S Padwal, Diana Rucker, Stephanie K Li, Cintia Curioni, David CW Lau, Raj S Padwal. 2003. Long-term pharmacotherapy for obesity and overweight. .
CrossRef
